艾灸联合中药汤剂防治早期乳腺癌化疗所致骨髓抑制的随机对照试验研究方案
本研究为单盲随机对照试验,纳入早期乳腺癌化疗患者462例,随机分为对照组、中药汤剂联合艾灸组和安慰剂联合艾灸组,评估艾灸联合温肾生白汤对化疗所致骨髓抑制的预防和治疗效果,主要结局包括白细胞减少缓解比例、骨髓抑制相关严重不良事件及rhG-CSF用量。
要点
- 艾灸联合温肾生白汤可能减轻早期乳腺癌化疗所致骨髓抑制。
- 研究采用单盲设计,按年龄、化疗方案和化疗策略分层随机。
- 主要结局包括白细胞减少缓解比例、严重不良事件和rhG-CSF用量。
核心结论
- 该研究旨在评估艾灸联合中药汤剂对早期乳腺癌化疗所致骨髓抑制的防治效果,并为标准化中药汤剂和艾灸方法提供证据。
研究设计与样本
- 随机对照单盲试验,中药汤剂设盲但艾灸不设盲,按年龄、化疗方案和化疗策略分层。
- 计划纳入462例早期乳腺癌患者,每组154例,分为对照组、中药汤剂联合艾灸组和安慰剂联合艾灸组。
关键数值与推荐
- 主要结局包括白细胞减少和/或中性粒细胞减少缓解的患者比例、骨髓抑制相关严重不良事件(包括3-4级白细胞减少和/或中性粒细胞减少及发热性中性粒细胞减少)以及rhG-CSF剂量。
- 次要结局包括化疗依从性、分层分析、不良反应、EORTC乳腺癌特异性生活质量问卷(QLQ-C30 V3.0和QLQ-BR23)评估的生活质量、中医体质以及3年无病生存和总生存。
临床怎么用
- 若证实有效,艾灸联合温肾生白汤可作为早期乳腺癌化疗所致骨髓抑制的辅助防治手段。
局限性
- 研究方案阶段,尚未报告实际干预效果数据。
- 艾灸未设盲,可能存在实施偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traditional Chinese medicine (TCM) has a long history of use in breast cancer, but lacking systematic evidence to support its clinical benefits. In this study, we evaluated the prophylactic and therapeutic effects of moxibustion combined with decoctions for treating chemotherapy-induced myelosuppression (CIM) in early-stage breast cancer patients. METHODS: This is a randomized controlled clinical trial single-blinded for TCM decoction but not moxibustion. Patients are equally divided into the control group without decoction and moxibustion treatment (control), the decoction+moxibustion group (MD), and the placebo+moxibustion group (MP), according to the following stratification factors: age (below 40s, 40s, 50s, and 60s or above), chemotherapy regimen (anthracyclines, taxanes, anthracyclines+taxane, and others), and chemotherapy strategy (adjuvant and neoadjuvant). The TCM decoction is Wenshen Shengbai Decoction. The anticipated sample size is 462 cases (154 cases in each group). All participants are expected to treat with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF). The primary outcomes include the proportion of patients with relief of leukopenia and/or neutropenia, the myelosuppression-associated serious adverse event including grade 3-4 leukopenia and/or neutropenia, and febrile neutropenia, and the dose of rhG-CSF. The secondary outcomes include chemotherapy adherence, stratified analysis, adverse reactions, quality of life by EORTC Breast-Cancer-Specific Quality of Life Questionnaire including EORTC QLQ-C30 (V3.0) and QLQ-BR23, TCM Constitution, and 3-year disease-free survival and overall survival. Baseline information including age, surgical approach, chemotherapy regimen and strategy, pathological stage, and molecular subtype will be recorded. DISCUSSION: This will be the first randomized controlled trial to evaluate the efficacy of moxibustion combined with TCM decoction in treating CIM in early-stage breast cancer patients, aiming to standardize the TCM decoction and moxibustion method, thus providing evidence for its clinical benefit. TRIAL REGISTRATION: chictr.org.cn ChiCTR-INR-16009557 . Registered on 23 October 2016.
引用
- Ji Y, Li S, Zhang X, et al. The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial. Trials. 2020. PMID: 33046128. doi:10.1186/s13063-020-04749-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。